Mortality in Dementia from 1996 to 2015: A National Registry-Based Cohort Study

Lærke Taudorf\textsuperscript{a,∗}, Ane Nørgaard\textsuperscript{a}, Gunhild Waldemar\textsuperscript{a,b} and Thomas Munk Laursen\textsuperscript{c}

\textsuperscript{a}Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
\textsuperscript{b}Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
\textsuperscript{c}National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus BSS, Aarhus University, Aarhus, Denmark

Handling Associate Editor: Anders Wimo

Accepted 19 October 2020

Abstract

Background: It remains unclear whether the increased focus on improving healthcare and providing appropriate care for people with dementia has affected mortality.

Objective: To assess survival and to conduct a time trend analysis of annual mortality rate ratios (MRR) of dementia based on healthcare data from an entire national population.

Methods: We assessed survival and annual MRR in all residents of Denmark \( \geq 65 \) years from 1996–2015 using longitudinal registry data on dementia status and demographics. For comparison, mortality and survival were calculated for acute ischemic heart disease (IHD) and cancer.

Results: The population comprised 1,999,366 people (17,541,315 person years). There were 165,716 people (529,629 person years) registered with dementia, 131,321 of whom died. From 1996–2015, the age-adjusted MRR for dementia declined (women: 2.76 to 2.05; men: 3.10 to 1.99) at a similar rate to elderly people without dementia. The sex-, age-, and calendar-year-adjusted MRR was 2.91 (95% CI: 2.90–2.93) for people with dementia. MRR declined significantly more for acute IHD and cancer. In people with dementia, the five-year survival for most age-groups was at a similar level or lower as that for acute IHD and cancer.

Conclusion: Although mortality rates declined over the 20-year period, MRR stayed higher for people with dementia, while the MRR gap, compared with elderly people without dementia, remained unchanged. For the comparison, during the same period, the MRR gap narrowed between people with and without acute IHD and cancer. Consequently, initiatives for improving health and decreasing mortality in dementia are still highly relevant.

Keywords: Dementia, mortality, nationwide study, survival, time trend

INTRODUCTION

During the last two decades, there has been increased focus on improving health in the rapidly increasing elderly population [1, 2]. These initiatives are important for maintaining good quality of life for the individual, for increased life expectancy, and for limiting societal economic costs. With age as the predominant risk factor for dementia, prevalence of dementia worldwide is expected to increase considerably from 46.8 million in 2015 to 131.5 million by 2040 [1].

Even though mortality is markedly increased in dementia [3], it may not be perceived of as a fatal disease in the same way as acute ischemic heart disease (IHD) and cancer are, for example.

Currently, no cure or disease-modifying treatments for dementia are available [4]. The existing antide-mentia drugs are only symptomatic, with documented

ISSN 1387-2877/21/$35.00 © 2021 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).
efficacy on Alzheimer’s disease, Lewy body demen-
tia, and Parkinson’s disease with dementia. Dementia 
research has nonetheless seen a variety of other 
improvements occur in recent decades, including the 
acquisition of greater knowledge about the under-
yling pathophysiological changes, leading to better 
and more precise diagnostics and, thus, also improve-
ments in the evaluation and management of dementia. 
Consequently, these changes have been accompanied 
by increased awareness, a change in the perception 
of dementia disorders as brain disorders, and greater 
knowledge about the need for psychosocial support, 
not to mention improved treatment of comorbidities. 
As in other high income countries, the most frequent 
causes of death in Denmark are heart disease and 
cancer [5, 6]. In the general population, these are 
perceived as life-threatening, where as a dementia 
disorder may not be perceived as a fatal condition. 
In contrast to dementia disorders, the treatment of 
acute IHD and cancer, including identification of risk 
factors, early detection, and novel disease modifying 
interventions, has improved markedly in the last 20 
years, leading to a significant decline in mortality. 
Hence, it is of interest to examine whether improve-
ments in the management of dementia disorders have 
been accompanied by a decline in mortality in people 
with dementia and then to put results into a context, 
comparing with changes in mortality in people with 
acute IHD and cancer.

Evidence for the time trend of mortality with 
dementia is scarce [7–11, 21]. Monitoring time trends 
is challenging as the date of dementia diagnosis must 
be linked to the date of death at an individual level. 
Of the six studies investigating changes in mortality 
in dementia over time, four found a declining trend 
in mortality rates in dementia [8, 10, 11, 21]. Nev-
evertheless, these results were based on small cohorts, 
covered only a few years, or included limited obser-
vation points in time. National Danish registries are 
uniquely poised to provide data enabling exploration 
of time trends of mortality in an entire population 
over decades [12].

We hypothesized that mortality was higher in 
people with dementia compared with the general pop-
ulation without dementia. Furthermore, we also sug-
gested that the mortality in people with dementia had 
decreased more rapidly than in the general population 
due to a higher awareness of providing appropriate 
care. The aim of this study was to assess time trends in 
all-cause mortality in people with dementia compared 
to the general elderly population using healthcare 
data from the entire population of Denmark from 
1996–2015. In addition, we aimed to compare all-
cause mortality in dementia with all-cause mortality 
in people with acute IHD and cancer. Finally, our 
goal was to study the current survival in people with 
dementia compared to both the general elderly pop-
ulation and people with acute IHD or cancer.

METHODS

Study setting

This cohort study was based on data from national 
Danish registries. Since 1968, the Danish Civil Regis-
tration System has provided all permanent residents 
with a unique 10-digit personal identification num-er that includes vital information on an individual 
level, such as date of birth and death [13]. This num-er enables individual linkage on demographic and 
healthcare data for the entire population [13].

Data sources

Danish Civil Registration System data was merged 
with data from three national registries. The first 
two, the Danish National Patient Registry and the 
Psychiatric Central Research Register, began regis-
tering data on all hospital admissions in 1977 and 
1969, respectively. Since 1995, they have also col-
lected data on contacts to emergency departments and 
hospital-based outpatient clinics [12]. Date of admis-
sion, date of discharge, and primary and optional 
secondary diagnoses have been registered accord-
ging to the International Classification of Diseases 
(ICD), 10th Revision at every patient contact since 
1994 [12]. Before then, ICD 8th Revision was in use 
[12]. The third registry, the Danish National Prescription 
Registry, has collected data on filled prescription 
medication since 1995 that includes date of dispens-
ing, dose, strength, and the anatomical therapeutic 
chemical code [14].

Study period

The observation period was defined as January 1, 
1996 to December 31, 2015. For the survival analyses 
calculating cumulative incidences, we restricted the 
study period to January 1, 2000 to December 31, 2015 
as we were unable to adjust for calendar period in the 
cumulative incidences and because 1996–2000 had a 
higher all-cause mortality and incidence of dementia 
than the subsequent period.
Study population

All Danish residents age ≥65 years as of January 1, 1996 were included in the assessment of mortality. During follow-up, people were included the day they turned 65 and then censored if they died, left the country permanently, were lost to follow-up, or at the end of the study period. When assessing mortality in dementia, individuals registered with dementia age <65 years were excluded due to our focus on late onset dementia, while individuals not registered with dementia served as the reference group. For comparison, mortality and survival were calculated for people age ≥65 years with acute IHD and cancer using the same methodology. Thus, the analysis assessing annual mortality rate ratios (MRRs) excluded individuals diagnosed with acute IHD and cancer age <65 years.

The methodology was adjusted in three ways to calculate cumulative incidences of death. First, the study period began January 1, 2000. Second, only incidence cases were assessed, which meant that people with dementia, acute IHD, and cancer diagnosed before January 1, 2000 were excluded from their respective analyses. Lastly, we constructed a group to represent the general population (see Supplementary Material). Apart from these adjustments, the same criteria for inclusion, exclusion, and censoring were used when assessing MRRs and cumulative incidence of death.

Definition of dementia, acute IHD, and cancer

Dementia was defined as either a registered dementia diagnosis (primary or secondary) in the Danish National Patient Registry or the Psychiatric Central Research Register (ICD–8 codes: 290.9–11, 290.18–19, 293.09–19; ICD–10 codes: F00.0–9, F01.0–9, F02.0, F03.9, G30.0–9, G31.8–9) or having filled a prescription for an antidementia drug (ATC-codes N06DA02 (donepezil), N06DA03 (rivastigmine), N06DA04 (galantamine), and N06DX01 (memantine)). Onset date was defined as the first contact with a registered dementia diagnosis, or a prescription filled for an antidementia drug, whichever came first. Denmark has universal tax-funded healthcare and less than one percent of hospital beds are in private hospitals [15]. When people experience symptoms of dementia, they usually make an appointment with their general practitioner, who performs a preliminary examination. If the general practitioner suspects dementia, the person is referred to a hospital memory clinic, which performs diagnostic evaluation. If symptoms are obvious and additional workup safely deemed unnecessary, the general practitioner may assign the diagnosis without referring the patient to the hospital. Another factor is that some people, though a highly limited number, are seen in a private healthcare setting. In an effort to include the last two groups mentioned, we used data on prescriptions filled for antidementia drugs.

The definition of acute IHD and cancer were based on diagnosis codes as defined in the Charlson Comorbidity Index (acute IHD, ICD–8 code: 410, ICD10-codes: I21–23; cancer: ICD–8 codes: 140–189, 195–199, 200–207, 275.59, ICD–10 codes: C00–85, C88, C90–96) [16].

Statistics

Mortality

Time trends in mortality in people with dementia from 1996 to 2015 were assessed by MRRs analyzed using Poisson regression analysis, which is equivalent to a Cox regression [17]. In our first model, the exposure was dementia and the outcome was death. All analyses were stratified by sex, as mortality differs among women and men. We tested whether there was a difference in the time trend of the mortality rates in people with dementia compared to the elderly population without dementia and chose the reference to be the mortality rate for women and men without dementia in 1996 (reference value was 1.00). Our second and third Poisson regression models were used to calculate MRR trends for individuals registered with acute IHD and cancer, respectively, compared to people without either disease using the same methods as described for dementia. Furthermore, we examined differences in change in mortality rates between people with dementia, acute IHD, cancer, and the total elderly population by assigning the reference value of 1.00 to all four groups in 1996. The assumption of piecewise constant intensity in the age groups was verified, as should be the case before applying a Poisson regression analysis [18].

Cumulative incidences

We assessed cumulative incidence rates of death in people registered with dementia, acute IHD, cancer, and in the general elderly population age ≥65 years from 2000–2015 using Kaplan-Meier analyses to calculate survival probabilities for women and men in strata of 5-year age groups (65–69, 70–74, 75–79, 80–84, 85–89, 90+). The Kaplan-Meier
methods cannot take changes due to calendar year properly into account. In order to try and limit the effect of changes related to calendar year, we chose to exclude the years 1996–1999 because mortality was highest in this period and our previous study showed a marked increase in incidence of dementia those years as well [19]. This left us with the time period from 2000–2015 when assessing survival. To prevent any identification of individual cases, the two oldest age groups were combined into one group of people aged ≥85 for the Kaplan-Meier curves, thus maintaining anonymity. In figures, the maximum follow-up time was also limited to ten years to preserve anonymity.

A p-value was considered significant at 0.05 for all analyses, which were performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA).

**Approvals and data availability**

This study was approved by the Danish Data Protection Agency (ID no.: 2007-58-0015/30-0667), Statistics Denmark, and the Danish Health and Medicines Authority (ID no.: 6-8011-907/1). As this study used anonymized data, Danish law does not require ethics committee approval or informed patient consent.

This study was based on data from nationwide public registries and, according to Danish law, sharing such datasets is not allowed. To gain access to Danish registry data, individual research projects must seek approval from the Danish Data Protection Agency. Hence, further data sharing of this project is not possible.

### RESULTS

Between 1996 and 2015, there were 1,999,366 people (women: 1,079,276; men: 920,090) age ≥65 years living in Denmark. They were observed over 17,541,315 person years (women: 9,912,480; men: 7,628,835), resulting in an average of 8.77 years at risk per person. There were 165,716 people living with a dementia diagnosis (women: 103,683; men: 62,033), observed over 529,629 person years (women: 353,211; men: 176,418). A total of 15,300 people with dementia was solely identified using prescription data.

In the same period, there were 144,380 people living with an acute IHD diagnosis (women: 65,622; men: 78,758), observed over 665,640 person years (women: 290,760; men: 374,880), and 400,610 people living with a cancer (women: 195,483; men: 205,127), observed over 1,565,110 person years (women: 841,299; men: 723,811).

The number of people with dementia who died was 131,321 (women: 81,855; men: 49,466). In the acute IHD group, the number of deaths was 109,154 (women: 51,172; men: 57,982), and in the cancer group, it was 283,143 (women: 137,834; men: 145,309).

Table 1 presents mortality rates and MRRs stratified by sex, age, and 5-year calendar periods for people with dementia compared with the general population without dementia.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Dementia</th>
<th>No dementia</th>
<th>MRR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>PY</td>
<td>MR</td>
</tr>
<tr>
<td>Women</td>
<td>81,855</td>
<td>353,211</td>
<td>231.7</td>
</tr>
<tr>
<td>Men</td>
<td>49,466</td>
<td>176,418</td>
<td>280.4</td>
</tr>
<tr>
<td>Age groups</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65–69</td>
<td>1767</td>
<td>17,127</td>
<td>103.2</td>
</tr>
<tr>
<td>70–74</td>
<td>7289</td>
<td>54,893</td>
<td>132.8</td>
</tr>
<tr>
<td>75–79</td>
<td>17,564</td>
<td>102,533</td>
<td>171.3</td>
</tr>
<tr>
<td>80–84</td>
<td>31,426</td>
<td>140,918</td>
<td>223.0</td>
</tr>
<tr>
<td>85–90</td>
<td>38,638</td>
<td>132,920</td>
<td>290.7</td>
</tr>
<tr>
<td>90+</td>
<td>34,637</td>
<td>81,239</td>
<td>426.4</td>
</tr>
<tr>
<td>Time periods</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996–2000</td>
<td>21,909</td>
<td>79,664</td>
<td>275.0</td>
</tr>
<tr>
<td>2001–2005</td>
<td>32,003</td>
<td>123,854</td>
<td>258.4</td>
</tr>
<tr>
<td>2006–2010</td>
<td>38,276</td>
<td>157,020</td>
<td>243.8</td>
</tr>
<tr>
<td>2011–2015</td>
<td>39,133</td>
<td>169,092</td>
<td>231.4</td>
</tr>
</tbody>
</table>

Mortality rates are listed in 1000 person years. MRR, mortality rate ratio; CI, confidence interval; n, number of deaths; PY, person years; MR, mortality rates; *, adjusted/stratified for age, calendar year, and sex; *p<0.00001.
with age from 5.54 (95% CI: 5.28–5.80) in people age 65–69 years to 2.08 (2.06–2.11) in people age ≥90 years. Sex- and age-adjusted MRRs were similar in 1996–2000, 2001–2005, 2006–2010, and 2011–2015.

Figure 1 presents the MRR time trends for women and men with and without dementia, acute IHD, and cancer. MRRs were significantly higher in dementia compared with people without dementia throughout the 20-year period. Similar trends were observed for acute IHD and cancer. Adjusted for age, sex, and calendar year, the MRR was 2.91 (95% CI: 2.90–2.93) in people with dementia compared with the general elderly population without dementia.

Fig. 1. Time trend of all-cause mortality for women and men. Graphs showing age-adjusted mortality rate ratios for women and men with dementia, acute ischemic heart disease (IHD), and cancer compared to people without. The reference value was defined as 1.00 in 1996 for women and men without dementia, acute IHD, and cancer. Error bars represent 95% confidence interval.
DISCUSSION

To our knowledge, this is the first study of time trends in mortality for dementia in an entire national population. In accordance with previous findings, our study confirmed that all-cause mortality rates in dementia were higher than in people without dementia [3]. Although MRRs in dementia declined over the 20-year period, it occurred at the same rate as in those without dementia, leaving the excess mortality in people with dementia unchanged. In contrast, the excess mortality from acute IHD and cancer was significantly reduced during the same period.

Our results highlight the fact that dementia is associated with increased mortality at all ages. Even though the MRRs were higher in the youngest of the elderly when comparing people with and without dementia, a dementia diagnosis was associated with significantly higher MRRs in women and men in all age groups. Furthermore, the 5-year probability of survival after a dementia diagnosis was largely comparable to the 5-year probability of survival after acute IHD or a cancer diagnosis. We believe this age-related difference in MRRs is associated to the fact that the risk of mortality increases with age, which means that it is generally high in people age...
Fig. 3. Survival for women and men. Age-stratified Kaplan-Meier survival curves for women and men with dementia, acute ischemic heart disease (IHD), cancer, and the general elderly population, 2000–2015.
>90 years. The risk of mortality is also affected by comorbidities, which are more frequent in the most elderly people. Thus, when comparing the people in the youngest dementia groups with the general elderly population in the same age group, the latter will have fewer comorbidities and are at a lower risk of dying. However, in the oldest age groups mortality rates are generally higher and the frequency of comorbidities are similar in people with and without dementia. Thus, in the youngest there is a greater difference in MRR between people with and without dementia because the background mortality is low and, compared to their peers, people with dementia have more comorbidities.

We found that, over a 20-year period, the age- and sex-adjusted MRR was about 2.9 times higher in people with dementia compared with people without dementia. In their meta-analysis, Dewey and Saz estimated a similarly increased mortality risk for people with dementia (odds ratio: 2.63, 95% CI: 2.17–3.21) [20]. However, only few studies have investigated time trends of mortality. Our findings of declining mortality are in line with findings from four population-based studies, one from Sweden, two from the Netherlands, and one from Japan [8, 10, 11, 21]. In contrast, two other studies found a tendency of increasing mortality in dementia. A German study based on health claims registry data from 2006–2007 to 2009–2010 found that mortality with dementia tended to be lower in the first period, although this was only significant in women [9]. This study observed mortality in dementia over a relatively short period. Similarly, a U.S. study based on data from a population-based longitudinal survey observed that the 2-year mortality was higher in individuals with moderate and severe cognitive impairment in 2002–2004 compared with 1993–1995 [7]. However, these results were not significant. To conclude, there is limited evidence of an increase in mortality in dementia, and our study results, based on data from an entire national elderly population over a 20-year period, add weight to the scientific evidence that mortality in dementia is declining.

From 1996–2015, the mortality rates declined more in men compared with women in the groups with dementia, cancer, and the general elderly population. For men and women with acute IHD, the mortality rates declined at a similar rate. Interestingly, life expectancy is higher in women than in men. From 2000–2015, this sex gap in Denmark narrowed by nearly one year [22]. Thus, we believe that the steeper decline in mortality rates seen in most groups of men may be explained by an increased life expectancy in men in general.
Most dementias are progressive, fatal brain diseases, which means that dementia alone contributes to an increased risk of death [23]. It is also well-established that increased mortality in dementia is related to the level of severity and subtype of dementia [24–28]. We did not investigate the potential contributors of other possible causes for the excess mortality in people with dementia found in our study. Previous studies suggest that increased mortality in dementia may also be related to polypharmacy [23, 29], antipsychotics [30], frailty [29, 31], co-occurring chronic conditions [24], and functional impairment [32]. Furthermore, it is possible that insufficient treatment of other health conditions, unhealthy lifestyle, and compromised access to healthcare due to a dementia diagnosis may contribute to the excess mortality.

We observed a decline in mortality rates in elderly people with and without dementia. There are several possible explanations for this finding. First, the health of the entire elderly population with and without dementia has generally improved. Second, increased awareness about dementia and improved dementia care during our study period may have also contributed to the decline in mortality. Third, an artificial decline in mortality rates of dementia unrelated to improved health may be due to earlier age at diagnosis. If there had been a shift towards earlier diagnosis while overall life expectancy remained unchanged, this would, somewhat misleadingly, result in increased survival after dementia diagnosis. Even though, our previous study on declining incidence of dementia in Denmark showed that median age at diagnosis did not change significantly from 1996 to 2015 [19], it is still possible that diagnoses towards the end of the study were registered at an earlier stage of the disease process.

The mortality gap between people with acute IHD or cancer and the general elderly population was reduced during the same 20-year period. The period covered by the present study saw the development of better and more efficacious treatments, just as the diseases we examined were and are a priority in the Danish healthcare sector, with full government support [33, 34]. For example, the treatment and organization of healthcare for acute IHD improved. From 1997–1998 to 2009–2010, the practice of revascularization (percutaneous coronary intervention) after onset of acute myocardial infarction increased from 2.5% to 38.2%, while the use of statins and clopidogrel also increased even more markedly [34].

Although multiple disease-modifying drugs against Alzheimer’s disease are in the pipeline, no new medications have been approved since 2003, and numerous attempts to find more effective drugs have failed [35]. Nonetheless, several actions can be taken to possibly reduce mortality in dementia, for instance, better treatment of comorbidities, a reduction in polypharmacy and inappropriate medications, and improved access to healthcare to reduce functional impairment and frailty in people with dementia.

This study also assessed survival after first diagnoses. For 1- and 5-year survival probabilities, we observed that survival was higher in the general elderly population, as compared to people with dementia, acute IHD, or cancer. Nonetheless, 1-year survival for women and men with dementia was significantly higher than for those with acute IHD and cancer. We believe this reflects the difference in the disease development and time course of the three conditions examined. Acute IHD has the highest mortality on the day of onset and closely after, which is why the general standard for reporting mortality is 30-day survival [36]. Our definition of cancer covers a broad range of cancer diseases with very large differences in disease progression patterns. The reason why the 1-year survival in cancer was lower than for dementia is related to the fact that some cancer types are fatal very early in the course of the disease, e.g., pancreas, liver, brain, lung, and esophagus cancer [37].

In terms of the 5-year survival probabilities, we observed different patterns for women and men when comparing dementia with cancer and acute IHD. In general, the 5-year survival probability for the three disease groups ranged from 0.72–0.11 in women and 0.74–0.04 in men, according to age groups. In women age <80 years, the 5-year survival was lowest in cancer, higher in dementia, and highest in acute IHD, whereas in women age ≥80 years, the three diseases are largely similar.

Overall, being diagnosed with dementia was more dangerous in men than a diagnosis of acute IHD and cancer. We believe that one of the reasons why survival in men with acute IHD was relatively high may be related to our selection of the group. From 1997–2010, the median age of first acute myocardial infarction in men was 64–66 years and 73–75 years in women [34]. The fact that we excluded people with a previous history of acute IHD prior to the age of 65 may have led to selection bias, possibly favoring men who were healthier than the average male with acute IHD.

This study, which is based on routine healthcare data from the secondary sector, has limitations.
Hence, for dementia, one of the limitations is that we do not have access to data on, e.g., cognitive status or physical performance status, that may affect mortality in dementia. Studies have shown that mortality differs according to the various subtypes of dementia [24–26]. We would be interested in performing additional analyses investigating subtypes but, even though the dementia syndrome diagnosis has high validity in Danish national registries, the validity of dementia subtype diagnoses is limited [38]. Our definition of cancer is heterogeneous. As mortality varies with cancer subtypes [33], the time trend of mortality may have changed differently for the various subtypes during our study period. Furthermore, the steep decrease in cancer mortality may partly be mediated by earlier time of diagnosis due to screening regimes for some cancer subtypes. In addition, not everyone with dementia is registered in our secondary healthcare registries. Our previous study showed that there were 36,129 people age ≥65 years registered with dementia in Denmark in 2015 [19]. Nevertheless, extrapolations from population-based studies estimate the prevalence of dementia in Denmark to be around 87,000 [39]. Thus, a considerable number of people with dementia are either undiagnosed or diagnosed in primary care only. We hypothesize that possibly unregistered individuals with dementia may represent those with the mildest and the most severe symptoms. The inability to include these groups may have influenced our results. However, having the entire Danish elderly population as our reference group we believe the contamination of the comparison group is limited. Thus, the underreporting of dementia in the registries may only lead to a limited underestimate of the association between dementia and excess mortality.

Among the strengths of our study is the use of data from an entire large, unselected national cohort with minimal dropout, no missing data, and a large sample size. Second, our data is continuous in terms of time, enabling us to assess time trends at yearly intervals. This strengthens our time trend analysis as compared to only comparing two or a few points in time. The validity of dementia syndrome diagnoses in the Danish registries used in this study has been assessed and found to be correct in 85.8% of cases [38]. We believe our results are generalizable to high-income Western countries with similar improvements in health in the elderly population over the last 20 years and with equal access to healthcare.

Conclusion

This study demonstrated that dementia is associated with a considerably increased mortality in women and men of all age groups. The mortality rates declined for dementia over the 20-year period under study. However, contrary to our hypothesis, we found that the mortality gap between people with dementia and the general elderly population was not reduced, despite a stronger focus on appropriate care for people with dementia during the study period. In the future, the discovery of more efficacious disease-modifying treatments may hopefully contribute to lower mortality. In the meantime, initiatives for improving health and decreasing mortality in people with dementia are still highly relevant and can include improving the treatment of comorbidities and the organization of support and healthcare services for people with dementia.

ACKNOWLEDGMENTS

The authors would like to thank the Danish Ministry of Health for supporting the Danish Dementia Research Centre. Additionally, the authors thank Kasper Jørgensen, Danish Dementia Research Centre, for his thorough review of this paper.

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/20-0823r1).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: http://dx.doi.org/10.3233/JAD-200823.

REFERENCES


